Empagliflozin and Atrial Fibrillation Treatment

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT04583813

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Miulli General Hospital (from the registry)
Registry
  • NCT NCT04583813
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04583813. Randomized; double masking; primary purpose treatment. Start 2021-09 (anticipated); primary completion 2024-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin and Atrial Fibrillation Treatment
Acronym
EMPA-AF
Condition
Heart Failure
Condition
Obesity
Condition
Diabetes Mellitus
Intervention (Drug)
Empagliflozin
Intervention (Other)
Placebo
Lead sponsor
Miulli General Hospital (class: other)

Record details

Record id
cardio:ct-nct04583813
Content hash
f90801a5150deacfa25cb4ed98618c4af7a2c5bdf261b366792357235619b60d